Suppr超能文献

一项住院临床药师服务的成本效益分析。

A cost-effectiveness analysis of an in-hospital clinical pharmacist service.

作者信息

Wallerstedt Susanna M, Bladh Lina, Ramsberg Joakim

机构信息

Department of Clinical Pharmacology, Sahlgrenska University Hospital, Göteborg, Sweden.

出版信息

BMJ Open. 2012 Jan 5;2(1):e000329. doi: 10.1136/bmjopen-2011-000329. Print 2012.

Abstract

Objective A randomised controlled study performed from 2007 to 2008 showed beneficial effects of a composite clinical pharmacist service as regards a simple health status instrument. The present study aimed to evaluate if the intervention was cost-effective when evaluated in a decision-theoretic model. Design A piggyback cost-effectiveness analysis from the healthcare perspective. Setting Two internal medicine wards at Sahlgrenska University Hospital, Göteborg, Sweden. Participants Of 345 patients (61% women; median age: 82 years; 181 control and 164 intervention patients), 240 patients (62% women, 82 years; 124 control and 116 intervention patients) had EuroQol-5 dimensions (EQ-5D) utility scores at baseline and at 6-month follow-up. Outcome measures Costs during a 6-month follow-up period in all patients and incremental cost-effectiveness ratio per quality-adjusted life-year (QALY) in patients with EQ-5D utility scores. Inpatient and outpatient care was extracted from the VEGA database. Drug costs were extracted from the Swedish Prescribed Drug Register. A probabilistic analysis was performed to characterise uncertainty in the cost-effectiveness model. Results No significant difference in costs between the randomisation groups was found; the mean total costs per individual±SD, intervention costs included, were €10 748±13 799 (intervention patients) and €10 344±14 728 (control patients) (p=0.79). For patients in the cost-effectiveness analysis, the corresponding costs were €10 912±13 999 and €9290±12 885. Intervention patients gained an additional 0.0051 QALYs (unadjusted) and 0.0035 QALYs (adjusted for baseline EQ-5D utility score). These figures result in an incremental cost-effectiveness ratio of €316 243 per unadjusted QALY and €463 371 per adjusted QALY. The probabilistic uncertainty analysis revealed that, at a willingness-to-pay of €50 000/QALY, the probability that the intervention was cost-effective was approximately 0.2. Conclusions The present study reveals that an intervention designed like this one is probably not cost-effective. The study thus illustrates that the complexity of healthcare requires thorough health economics evaluations rather than simplistic interpretation of data.

摘要

目的 一项于2007年至2008年开展的随机对照研究表明,综合临床药师服务在一种简单的健康状况评估工具方面具有有益效果。本研究旨在评估在决策理论模型中进行评估时该干预措施是否具有成本效益。

设计 从医疗保健角度进行附带成本效益分析。

设置 瑞典哥德堡萨尔格伦斯卡大学医院的两个内科病房。

参与者 345名患者(61%为女性;中位年龄:82岁;181名对照患者和164名干预患者)中,240名患者(62%为女性,82岁;124名对照患者和116名干预患者)在基线和6个月随访时具有欧洲五维健康量表(EQ-5D)效用评分。

结局指标 所有患者在6个月随访期内的成本,以及具有EQ-5D效用评分的患者每质量调整生命年(QALY)的增量成本效益比。住院和门诊护理数据从VEGA数据库提取。药品成本从瑞典处方药登记册提取。进行概率分析以描述成本效益模型中的不确定性。

结果 随机分组组之间在成本上未发现显著差异;包括干预成本在内,每名个体的平均总成本±标准差,干预组患者为10748±13799欧元,对照组患者为10344±十四728欧元(p = 0.79)。对于成本效益分析中的患者,相应成本分别为10912±13999欧元和9290±12885欧元。干预组患者额外获得了0.0051个QALY(未调整)和0.0035个QALY(根据基线EQ-5D效用评分调整)。这些数字得出每未调整QALY的增量成本效益比为316243欧元,每调整QALY为463371欧元。概率不确定性分析显示,在支付意愿为50000欧元/QALY时,该干预措施具有成本效益的概率约为0.2。

结论 本研究表明,这样设计的干预措施可能不具有成本效益。该研究因此说明,医疗保健的复杂性需要进行全面的卫生经济学评估,而不是对数据进行简单化解读。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e715/3253415/2bcdf86f8afc/bmjopen-2011-000329fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验